Metastatic Clinical Trial
Official title:
Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial
To explore the safety and efficacy of Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial. Meanwhile, Exploring the maximum tolerant dose or recommended II research dose of Surufatinib combined with a fixed dose of Sintilimab and Capecitabine using 3 + 3 dose climbing experiment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04333706 -
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05730673 -
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT01703585 -
Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples
|
||
| Completed |
NCT01216345 -
Cetuximab + Gemox in Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT00509964 -
Second-Line Irinotecan vs. ILF for AGC
|
Phase 2 | |
| Active, not recruiting |
NCT02069730 -
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
|
N/A | |
| Completed |
NCT01745757 -
Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer
|
||
| Completed |
NCT01633645 -
Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT04602117 -
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05496686 -
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
|
Phase 1 | |
| Completed |
NCT02639026 -
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
|
Phase 1 | |
| Completed |
NCT01719744 -
Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT05673811 -
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05868226 -
PRE-I-SPY Phase I/Ib Oncology Platform Program
|
Phase 1 | |
| Completed |
NCT00498797 -
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
|
Phase 2 | |
| Completed |
NCT00507091 -
Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination
|
Phase 1 | |
| Recruiting |
NCT06007937 -
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01974752 -
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
|
Phase 3 |